US-China Biomedical Technology, Inc. (UCBB) financial statements (2021 and earlier)

Company profile

Business Address 2 PARK PLAZA, SUITE 400
IRVINE, CA 92614
State of Incorp. NV
Fiscal Year End February 28
SIC 7311 - Advertising Agencies (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

2/28/2019
2/28/2018
2/28/2017
2/29/2016
2/28/2015
2/28/2014
2/28/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments3756330087
Cash and cash equivalents3756330087
Receivables    57  
Prepaid expense2253 0 
Deposits current assets  00000
Total current assets:58616357088
Noncurrent Assets
Deposits noncurrent assets1919     
Total noncurrent assets:1919     
Other undisclosed assets    (0)  
TOTAL ASSETS:77816357088
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities284614318810031
Accounts payable22181431297926
Employee-related liabilities628  59  
Accounts payable and other accrued liabilities215
Debt 45     
Deferred rent credit8
Due to related parties2261   51 
Total current liabilities:3835214318815131
Noncurrent Liabilities
Other undisclosed liabilities39      
Total liabilities:7635214318815131
Stockholders' equity
Stockholders' equity attributable to parent, including:1(272)(8)(28)(31)(150)56
Common stock161413131310097
Additional paid in capital2,9231,9411,7231,6581,5981,171361
Accumulated deficit(2,937)(2,226)(1,744)(1,699)(1,642)  
Other undisclosed stockholders' equity attributable to parent     (1,422)(402)
Total stockholders' equity:1(272)(8)(28)(31)(150)56
TOTAL LIABILITIES AND EQUITY:77816357088

Income statement (P&L) ($ in thousands)

2/28/2019
2/28/2018
2/28/2017
2/29/2016
2/28/2015
2/28/2014
2/28/2013
Operating expenses(522)(516)(44)(56)(219)(342)(261)
Other operating income, net
(Other Expenses)
     174 
Other undisclosed operating loss     (677) 
Operating loss:(522)(516)(44)(56)(219)(845)(261)
Nonoperating expense
(Other Nonoperating expense)
(188)      
Interest and debt expense(4)34    (1)
Loss from continuing operations before equity method investments, income taxes:(714)(481)(44)(56)(219)(845)(262)
Other undisclosed income (loss) from continuing operations before income taxes40   (174) 
Loss from continuing operations before income taxes:(710)(481)(44)(56)(219)(1,019)(262)
Income tax expense(1)(1)(1)(1)(1)(1)(1)
Net loss available to common stockholders, diluted:(711)(482)(45)(57)(220)(1,020)(263)

Comprehensive Income ($ in thousands)

2/28/2019
2/28/2018
2/28/2017
2/29/2016
2/28/2015
2/28/2014
2/28/2013
Net loss:(711)(482)(45)(57)(220)(1,020)(263)
Comprehensive loss, net of tax, attributable to parent:(711)(482)(45)(57)(220)(1,020)(263)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: